316 related articles for article (PubMed ID: 18559609)
1. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
[TBL] [Abstract][Full Text] [Related]
2. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
Giannoudis A; Davies A; Lucas CM; Harris RJ; Pirmohamed M; Clark RE
Blood; 2008 Oct; 112(8):3348-54. PubMed ID: 18669873
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
[TBL] [Abstract][Full Text] [Related]
4. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
5. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
Gromicho M; Dinis J; Magalhães M; Fernandes AR; Tavares P; Laires A; Rueff J; Rodrigues AS
Leuk Lymphoma; 2011 Oct; 52(10):1980-90. PubMed ID: 21663515
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.
Davies A; Jordanides NE; Giannoudis A; Lucas CM; Hatziieremia S; Harris RJ; Jørgensen HG; Holyoake TL; Pirmohamed M; Clark RE; Mountford JC
Leukemia; 2009 Nov; 23(11):1999-2006. PubMed ID: 19710702
[TBL] [Abstract][Full Text] [Related]
7. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib.
Glodkowska-Mrowka E; Mrowka P; Basak GW; Niesiobedzka-Krezel J; Seferynska I; Wlodarski PK; Jakobisiak M; Stoklosa T
Exp Hematol; 2014 Jun; 42(6):439-47. PubMed ID: 24667683
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.
Engler JR; Frede A; Saunders VA; Zannettino AC; Hughes TP; White DL
Leukemia; 2010 Apr; 24(4):765-70. PubMed ID: 20147974
[TBL] [Abstract][Full Text] [Related]
9. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
Wang L; Giannoudis A; Lane S; Williamson P; Pirmohamed M; Clark RE
Clin Pharmacol Ther; 2008 Feb; 83(2):258-64. PubMed ID: 17568400
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
11. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
[TBL] [Abstract][Full Text] [Related]
12. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
White DL; Saunders VA; Dang P; Engler J; Zannettino AC; Cambareri AC; Quinn SR; Manley PW; Hughes TP
Blood; 2006 Jul; 108(2):697-704. PubMed ID: 16597591
[TBL] [Abstract][Full Text] [Related]
13. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
14. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.
Hiwase DK; Saunders VA; Nievergall E; Ross DD; White DL; Hughes TP
Haematologica; 2013 Jun; 98(6):896-900. PubMed ID: 23065516
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
17. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
Turrini E; Haenisch S; Laechelt S; Diewock T; Bruhn O; Cascorbi I
Pharmacogenet Genomics; 2012 Mar; 22(3):198-205. PubMed ID: 22241070
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells.
Lu L; Saunders VA; Leclercq TM; Hughes TP; White DL
Leukemia; 2015 Aug; 29(8):1792-4. PubMed ID: 25676419
[No Abstract] [Full Text] [Related]
20. Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.
Malhotra H; Sharma P; Malhotra B; Bhargava S; Jasuja S; Kumar M
Indian J Med Res; 2015 Aug; 142(2):175-82. PubMed ID: 26354214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
